Oncology

The cancer community must seize the opportunity of the Natio...

With the government’s National Cancer Plan due for publication this autumn, we have an opportunity to fundamentally improve how we deliver innovation.

News

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.

News

FDA clears subcutaneous Keytruda in a boost to MSD

MSD's Keytruda will soon be available as a subcutaneous injection, improving convenience for patients and defending it from a looming patent loss.

Oncology

Prostate Cancer Awareness blue ribbon on blue background

Current and future standard of care in prostate cancer

Despite recent advancements in the field of prostate cancer treatment, there remain distinct gaps in the current standard of care needing improvement.

News